Cargando…

Medical treatment options for COVID-19

Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Delang, Leen, Neyts, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235633/
https://www.ncbi.nlm.nih.gov/pubmed/32363880
http://dx.doi.org/10.1177/2048872620922790
_version_ 1783536000172032000
author Delang, Leen
Neyts, Johan
author_facet Delang, Leen
Neyts, Johan
author_sort Delang, Leen
collection PubMed
description Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019.
format Online
Article
Text
id pubmed-7235633
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72356332020-05-20 Medical treatment options for COVID-19 Delang, Leen Neyts, Johan Eur Heart J Acute Cardiovasc Care Reviews Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019. Oxford University Press 2020-04-01 /pmc/articles/PMC7235633/ /pubmed/32363880 http://dx.doi.org/10.1177/2048872620922790 Text en © The European Society of Cardiology 2020 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reviews
Delang, Leen
Neyts, Johan
Medical treatment options for COVID-19
title Medical treatment options for COVID-19
title_full Medical treatment options for COVID-19
title_fullStr Medical treatment options for COVID-19
title_full_unstemmed Medical treatment options for COVID-19
title_short Medical treatment options for COVID-19
title_sort medical treatment options for covid-19
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235633/
https://www.ncbi.nlm.nih.gov/pubmed/32363880
http://dx.doi.org/10.1177/2048872620922790
work_keys_str_mv AT delangleen medicaltreatmentoptionsforcovid19
AT neytsjohan medicaltreatmentoptionsforcovid19